JP2013515013A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013515013A5 JP2013515013A5 JP2012545019A JP2012545019A JP2013515013A5 JP 2013515013 A5 JP2013515013 A5 JP 2013515013A5 JP 2012545019 A JP2012545019 A JP 2012545019A JP 2012545019 A JP2012545019 A JP 2012545019A JP 2013515013 A5 JP2013515013 A5 JP 2013515013A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- amino acid
- acid sequence
- antibody fragment
- fragment according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2009906286 | 2009-12-24 | ||
| AU2009906286A AU2009906286A0 (en) | 2009-12-24 | Anti P2X7 receptor antibodies and fragments thereof | |
| PCT/AU2010/001741 WO2011075789A1 (en) | 2009-12-24 | 2010-12-23 | Antibodies to non-functional oligomeric p2x7 receptors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013515013A JP2013515013A (ja) | 2013-05-02 |
| JP2013515013A5 true JP2013515013A5 (enExample) | 2014-02-13 |
| JP5992831B2 JP5992831B2 (ja) | 2016-09-14 |
Family
ID=44194835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012545019A Active JP5992831B2 (ja) | 2009-12-24 | 2010-12-23 | 非機能性オリゴマーｐ２ｘ７受容体に対する抗体 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US8835609B2 (enExample) |
| EP (2) | EP2516470B1 (enExample) |
| JP (1) | JP5992831B2 (enExample) |
| CN (1) | CN102762595B (enExample) |
| AU (1) | AU2010336032C1 (enExample) |
| BR (1) | BR112012015561B1 (enExample) |
| CA (1) | CA2784345C (enExample) |
| ES (2) | ES2732021T3 (enExample) |
| WO (1) | WO2011075789A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101555283B (zh) | 2001-01-17 | 2012-03-21 | 生物权威国际有限公司 | 针对非功能性p2x7受体的抗体及其在癌症和其它病情的诊断和治疗中的用途 |
| JP5670192B2 (ja) | 2007-09-14 | 2015-02-18 | バイオセプター・インターナショナル・リミテッド | 新規ｐ２ｘ７エピトープ |
| WO2009033234A1 (en) | 2007-09-14 | 2009-03-19 | Biosceptre International Limited | Purinergic (p2x) receptors in extra-cellular body fluid |
| AU2009266430B2 (en) | 2008-07-04 | 2014-08-14 | Biosceptre International Limited | Anti- P2X7 peptides and epitopes |
| EP3395832B1 (en) | 2009-08-20 | 2021-11-24 | Biosceptre (Aust) Pty Ltd | Anti p2x7 receptor antibodies and fragments thereof |
| EP2516470B1 (en) | 2009-12-24 | 2018-02-07 | Biosceptre (Aust) Pty Ltd | Antibodies to non-functional oligomeric p2x7 receptors |
| WO2012031333A1 (en) | 2010-09-10 | 2012-03-15 | Biosceptre International Limited | Companion animal treatments |
| WO2013003895A1 (en) * | 2011-07-01 | 2013-01-10 | Biosceptre International Limited | Combination therapy |
| WO2014003137A1 (ja) * | 2012-06-27 | 2014-01-03 | 旭化成メディカル株式会社 | 高アフィニティー抗体、及びその製造方法 |
| CN107614528A (zh) * | 2015-04-02 | 2018-01-19 | 生物权威（英国）有限公司 | 疼痛治疗 |
| US12121539B2 (en) * | 2015-09-11 | 2024-10-22 | Biosceptre (Aust) Pty Ltd | Chimeric antigen receptors and uses thereof |
| CN109862883A (zh) | 2016-10-21 | 2019-06-07 | 生物权威（英国）有限公司 | 细胞毒性颗粒 |
| WO2019165326A1 (en) * | 2018-02-23 | 2019-08-29 | REMD Biotherapeutics, Inc | Calcitonin gene-related peptide (cgrp) antagonist antibodies |
| AU2019275479B2 (en) | 2018-05-21 | 2022-12-08 | Biosceptre (Aust) Pty Ltd | Chimeric antigen receptors with modified linker domains and uses thereof |
| US11578125B2 (en) | 2018-05-29 | 2023-02-14 | Teknologian Tutkimuskeskus Vtt Oy | Anti-thyroid hormone (T4) recombinant antibody or antigen binding fragment |
| CN110054691B (zh) * | 2019-05-09 | 2021-09-07 | 潍坊医学院 | 一种抗人p2rx7单克隆抗体的杂交瘤细胞系 |
| JP7853205B2 (ja) * | 2019-07-26 | 2026-04-28 | バイオセプター （オースト） プロプライエタリー・リミテッド | Ｐ２ｘ７受容体の標的療法 |
| CA3211323A1 (en) * | 2021-03-11 | 2022-09-15 | Patrick Schlegel | Novel cell therapy system |
| JP2024532482A (ja) * | 2021-09-01 | 2024-09-05 | バイオセプター （オースト） プロプライエタリー・リミテッド | 免疫活性を刺激するための方法および組成物 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE920765A1 (en) | 1991-03-12 | 1992-09-23 | Scripps Research Inst | Cell surface receptors homologous to coagulation factors v¹and viii |
| EP0760850A1 (en) | 1994-05-27 | 1997-03-12 | Glaxo Group Limited | P2x RECEPTORS (PURINOCEPTOR FAMILY) |
| US5981218A (en) | 1995-08-09 | 1999-11-09 | Bristol-Myers Squibb Company | Isolated nucleic acid molecules useful as leukemia markers and in breast cancer prognosis and encoded polypeptides |
| JP2001521372A (ja) | 1996-04-30 | 2001-11-06 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | ヒトＰ２ｘ４レセプタースプライス−変異体 |
| US6303338B1 (en) | 1996-08-16 | 2001-10-16 | Human Genome Sciences, Inc. | Pancreas-derived plasminogen activator inhibitor |
| US6306393B1 (en) | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| JP3885177B2 (ja) | 1997-03-26 | 2007-02-21 | 大塚製薬株式会社 | ヒト遺伝子 |
| US6133434A (en) | 1997-04-28 | 2000-10-17 | Glaxo Group Limited | Purinergic receptor |
| DE69941187D1 (de) | 1998-06-01 | 2009-09-10 | Agensys Inc | Serpentintransmembranantigene exprimiert in menschlichem krebs und deren verwendungen |
| DE19829473C2 (de) | 1998-07-01 | 2000-08-10 | Magnus Von Knebel Doeberitz Ch | Verfahren zur frühen Diagnose von Carcinomen |
| EP1157038A4 (en) | 1999-02-26 | 2005-01-19 | Smithkline Beecham Corp | CLONING OF A P2Y-LIKE 7TM RECEPTOR (AXOR17) |
| AUPP991199A0 (en) | 1999-04-21 | 1999-05-13 | University Of Sydney, The | Methods for diagnosing pre-cancerous and cancerous conditions |
| WO2001030964A2 (en) | 1999-10-22 | 2001-05-03 | Lifespan Biosciences, Inc. | Anti-cancer nucleic acid and protein targets |
| AUPR201500A0 (en) | 2000-12-11 | 2001-01-11 | Biosceptre Pty Ltd | Methods for identifying pre-neoplastic and neoplastic states in mammals |
| WO2003020762A1 (en) | 2001-09-03 | 2003-03-13 | Intreat Pty Limited | Antibodies to non-functional p2x7receptor, diagnosis and treatment of cancers and other conditions |
| CN101555283B (zh) | 2001-01-17 | 2012-03-21 | 生物权威国际有限公司 | 针对非功能性p2x7受体的抗体及其在癌症和其它病情的诊断和治疗中的用途 |
| PL1469072T3 (pl) | 2003-04-17 | 2008-03-31 | Affectis Pharmaceuticals Ag | Środki i sposoby diagnozowania i leczenia chorób afektywnych |
| US20090215727A1 (en) | 2005-05-05 | 2009-08-27 | Medicure International Inc. | Inhibition of atp-mediated, p2x7 dependent pathways by pyridoxal-5-phosphate and vitamin b6 related compounds |
| US7767789B2 (en) | 2005-06-02 | 2010-08-03 | University Hopitals of Cleveland | Truncated proteins as cancer markers |
| WO2007027957A2 (en) | 2005-08-31 | 2007-03-08 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in leukemia signaling pathways |
| WO2008043145A1 (en) * | 2006-10-10 | 2008-04-17 | Biosceptre International Limited | Hybridomas producing antibodies against non functional p2x7 receptor |
| US20100036101A1 (en) | 2006-10-10 | 2010-02-11 | Angus Gidley-Baird | Antibodies against non functional p2x7 receptor |
| JP5670192B2 (ja) * | 2007-09-14 | 2015-02-18 | バイオセプター・インターナショナル・リミテッド | 新規ｐ２ｘ７エピトープ |
| WO2009033234A1 (en) | 2007-09-14 | 2009-03-19 | Biosceptre International Limited | Purinergic (p2x) receptors in extra-cellular body fluid |
| AU2009266430B2 (en) | 2008-07-04 | 2014-08-14 | Biosceptre International Limited | Anti- P2X7 peptides and epitopes |
| EP3395832B1 (en) | 2009-08-20 | 2021-11-24 | Biosceptre (Aust) Pty Ltd | Anti p2x7 receptor antibodies and fragments thereof |
| EP2516470B1 (en) | 2009-12-24 | 2018-02-07 | Biosceptre (Aust) Pty Ltd | Antibodies to non-functional oligomeric p2x7 receptors |
| WO2011131472A1 (en) | 2010-04-22 | 2011-10-27 | Institut Gustave Roussy | Compounds and uses thereof to induce an immunogenic cancer cell death in a subject |
| WO2012031333A1 (en) | 2010-09-10 | 2012-03-15 | Biosceptre International Limited | Companion animal treatments |
| WO2013003895A1 (en) | 2011-07-01 | 2013-01-10 | Biosceptre International Limited | Combination therapy |
-
2010
- 2010-12-23 EP EP10838429.8A patent/EP2516470B1/en active Active
- 2010-12-23 AU AU2010336032A patent/AU2010336032C1/en active Active
- 2010-12-23 ES ES17209838T patent/ES2732021T3/es active Active
- 2010-12-23 US US13/518,382 patent/US8835609B2/en active Active
- 2010-12-23 WO PCT/AU2010/001741 patent/WO2011075789A1/en not_active Ceased
- 2010-12-23 CN CN201080063868.6A patent/CN102762595B/zh active Active
- 2010-12-23 CA CA2784345A patent/CA2784345C/en active Active
- 2010-12-23 EP EP17209838.6A patent/EP3321285B1/en active Active
- 2010-12-23 JP JP2012545019A patent/JP5992831B2/ja active Active
- 2010-12-23 BR BR112012015561-0A patent/BR112012015561B1/pt active IP Right Grant
- 2010-12-23 ES ES10838429.8T patent/ES2667003T3/es active Active
-
2014
- 2014-08-11 US US14/456,898 patent/US9428587B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014511179A5 (enExample) | ||
| JP2013502204A5 (enExample) | ||
| JP2009532336A5 (enExample) | ||
| JP2017052784A5 (enExample) | ||
| JP2013506428A5 (enExample) | ||
| RU2017126476A (ru) | Новые модуляторы и способы их применения | |
| JP2020079246A5 (enExample) | ||
| JP2014526898A5 (enExample) | ||
| JP2009225799A5 (enExample) | ||
| JP2016516400A5 (enExample) | ||
| JP2013198490A5 (enExample) | ||
| JP2013538057A5 (enExample) | ||
| JP2021514973A5 (enExample) | ||
| HRP20170568T1 (hr) | Protutijela anti-ox40 i postupci za njihovu uporabu | |
| JP2018504105A5 (enExample) | ||
| JP2015530971A5 (enExample) | ||
| JP2020502271A5 (enExample) | ||
| NZ598670A (en) | Antibodies against glucagon receptor and their use | |
| NZ608206A (en) | Antibodies that bind myostatin, compositions and methods | |
| JP2018512379A5 (enExample) | ||
| HRP20211444T1 (hr) | Anti-dll3 antitijelo | |
| JP2011207882A5 (enExample) | ||
| JP2017500028A5 (enExample) | ||
| JP2017519759A5 (enExample) | ||
| JP2010042025A5 (enExample) |